Post-earnings recap
Reported
Tue, Feb 18, 2025
EPS actual
$-1.54
EPS est.
$-0.90
EPS surprise
-71.68%
1-day move
-2.33%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Axsome Therapeutics reported a significant miss on EPS, which contributed to a 2.33% decline in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's future performance. Management's focus on clinical trials suggests they are prioritizing long-term growth over short-term results.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.54 | N/A | -71.68% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding the current market conditions. They emphasized the importance of their ongoing research efforts.
Management did not provide specific guidance for future quarters.
The company is focusing on its ongoing clinical trials and product development.